News releases from Allergan plc
New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand
January 28, 2019
Allergan Announces Increased Quarterly Dividend and Annual General Meeting of Shareholders Date
January 24, 2019
- First Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share to be Paid on March 15, 2019; Record Date of February 15, 2019 -
CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care
January 14, 2019
-- Television Personality Named as Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --
Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma
January 06, 2019
- These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year -
Allergan to Establish R&D Presence in Cambridge, Massachusetts
January 06, 2019
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Actio
January 02, 2019
Allergan to Report Fourth Quarter and Full Year 2018 Earnings and Host Conference Call and Webcast
January 02, 2019
Allergan plc (NYSE: AGN) today announced it intends to release fourth quarter and full year 2018 financial results on Tuesday, January 29, 2019, prior to the open of U.S. Financial Markets.
Allergan to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 23, 2018
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the 37th Annual J.P. Morgan Healthcare Conference in San...
Allergan Suspends Sales and Withdraws Supply of Textured Breast Implants in European Markets
December 19, 2018
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that the company has suspended sales of textured breast implants and tissue expanders and is withdrawing any...
Allergan Makes New Appointments to Finance Leadership Team
November 25, 2018
Allergan to Present at the 2018 Citi Global Healthcare Conference
November 20, 2018
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference...
Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)
November 19, 2018
- Application Seeks to Expand the AVYCAZ label to Include Treatment of cUTI and cIAI in Pediatric Patients 3 months of age and older -
Allergan to Present at Credit Suisse 27th Annual Healthcare Conference
November 05, 2018
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27th Annual Health Care Conference in...
Allergan Reports Third Quarter 2018 Results Including GAAP Net Revenues of $3.9 Billion
October 29, 2018
Allergan and The Allergan Foundation Support U.S. Veterans With "Heroes MAKE America" Sponsorship
October 22, 2018
- The Manufacturing Institute's Career Skills Program Connects Veterans with Potential Manufacturing Jobs -
Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American Academy of Ophthalmology Annual Meeting
October 19, 2018
- Allergan Hosting Analyst Event at the 2018 AAO Annual Meeting Including Conference Call and Webcast on Friday, October 26, at 6:30 p.m. Central Time (7:30 p.m. Eastern Time) -
Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
October 17, 2018
Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix
October 11, 2018
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix,...
Allergan Presents New Research at the American College of Gastroenterology Annual Scientific Meeting (ACG 2018)
October 08, 2018
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific...
Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease
October 05, 2018
- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab
Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®
October 04, 2018
Allergan plc (NYSE: AGN) today announced that the CoolSculpting® treatment received FDA clearance to treat the submandibular area. In addition, the FDA clearance was expanded to include patients with a...
Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers
October 03, 2018
Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast
October 01, 2018
Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.S. financial markets.
Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs
September 28, 2018
Allergan Announces FDA Acceptance of Supplemental New Drug Application For VRAYLAR® (cariprazine)
September 26, 2018
Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st
September 20, 2018
Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines
September 14, 2018
- Study met primary endpoint demonstrating that higher doses of BOTOX® Cosmetic produce greater duration of treatment effect -